Tokyo Tape
Sign in
← Oncolys BioPharma

Quarterly report · Q2

4588.TEDINET S100OV5V
Period2022-01-01 → 2022-06-30
Filed2022-08-05
StandardJapan GAAP
ConsolidatedNo
Data checks12 of 12 passed
Key figures · 47
MetricValuePeriodScopeSource row
Revenue¥426m2022-01-01 → 2022-06-30StandaloneNet sales
Revenue¥642m2021-01-01 → 2021-12-31StandaloneNet sales (5-year summary)
Revenue¥193m2021-01-01 → 2021-06-30StandaloneNet sales
Operating income−¥659m2022-01-01 → 2022-06-30StandaloneOperating income
Operating income−¥634m2021-01-01 → 2021-06-30StandaloneOperating income
Ordinary income−¥591m2022-01-01 → 2022-06-30StandaloneOrdinary income
Ordinary income−¥1.5bn2021-01-01 → 2021-12-31StandaloneOrdinary income loss (5-year summary)
Ordinary income−¥649m2021-01-01 → 2021-06-30StandaloneOrdinary income
Profit before tax−¥569m2022-01-01 → 2022-06-30StandaloneIncome before income taxes
Profit before tax−¥649m2021-01-01 → 2021-06-30StandaloneIncome before income taxes
Net income−¥571m2022-01-01 → 2022-06-30StandaloneProfit loss
Net income−¥1.6bn2021-01-01 → 2021-12-31StandaloneNet income loss (5-year summary)
Net income−¥651m2021-01-01 → 2021-06-30StandaloneProfit loss
Total assets¥3.5bnat 2022-06-30StandaloneAssets
Total assets¥4.3bnat 2021-12-31StandaloneAssets
Total assets¥5.2bnat 2021-06-30StandaloneTotal assets (5-year summary)
Total liabilities¥767mat 2022-06-30StandaloneLiabilities
Total liabilities¥698mat 2021-12-31StandaloneLiabilities
Net assets / equity¥2.7bnat 2022-06-30StandaloneNet assets
Net assets / equity¥3.6bnat 2021-12-31StandaloneNet assets
Net assets / equity¥4.5bnat 2021-06-30StandaloneNet assets (5-year summary)
Cash and deposits¥2.9bnat 2022-06-30StandaloneCash and deposits
Cash and deposits¥3.5bnat 2021-12-31StandaloneCash and deposits
Cash & equivalents¥2.6bnat 2022-06-30StandaloneCash and cash equivalents
Cash & equivalents¥3.2bnat 2021-12-31StandaloneCash and cash equivalents
Cash & equivalents¥4.4bnat 2021-06-30StandaloneCash and cash equivalents
Cash & equivalents¥1.8bnat 2020-12-31dStandaloneCash and cash equivalents
Operating cash flow−¥722m2022-01-01 → 2022-06-30StandaloneNet cash provided by used in operating activities
Operating cash flow−¥1.7bn2021-01-01 → 2021-12-31StandaloneNet cash provided by used in operating activities (5-year summary)
Operating cash flow−¥595m2021-01-01 → 2021-06-30StandaloneNet cash provided by used in operating activities
Investing cash flow¥21m2022-01-01 → 2022-06-30StandaloneNet cash provided by used in investment activities
Investing cash flow−¥942,0002021-01-01 → 2021-12-31StandaloneNet cash provided by used in investing activities (5-year summary)
Investing cash flow−¥327,0002021-01-01 → 2021-06-30StandaloneNet cash provided by used in investment activities
Financing cash flow¥30m2022-01-01 → 2022-06-30StandaloneNet cash provided by used in financing activities
Financing cash flow¥3.1bn2021-01-01 → 2021-12-31StandaloneNet cash provided by used in financing activities (5-year summary)
Financing cash flow¥3.1bn2021-01-01 → 2021-06-30StandaloneNet cash provided by used in financing activities
EPS (basic)¥-32.922022-01-01 → 2022-06-30StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-13.942022-04-01 → 2022-06-30dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-95.52021-01-01 → 2021-12-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-39.452021-01-01 → 2021-06-30StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-17.352021-04-01 → 2021-06-30dStandaloneBasic earnings loss per share (5-year summary)
Equity ratio77.9%at 2022-06-30StandaloneEquity to asset ratio (5-year summary)
Equity ratio83.6%at 2021-12-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio86.1%at 2021-06-30StandaloneEquity to asset ratio (5-year summary)
Shares issued17,405,200at 2022-06-30StandaloneTotal number of issued shares (5-year summary)
Shares issued17,405,200at 2021-12-31StandaloneTotal number of issued shares (5-year summary)
Shares issued17,340,900at 2021-06-30StandaloneTotal number of issued shares (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

All source rows · 451
ItemContextValueUnit
Payments for lease and guarantee deposits inv cfCurrentYTDDuration_NonConsolidatedMember－JPY
Proceeds from collection of lease and guarantee deposits inv cfPrior1YTDDuration_NonConsolidatedMember－JPY
Proceeds from collection of lease and guarantee deposits inv cfCurrentYTDDuration_NonConsolidatedMember71000JPY
Net cash provided by used in investment activitiesPrior1YTDDuration_NonConsolidatedMember-327000JPY
Net cash provided by used in investment activitiesCurrentYTDDuration_NonConsolidatedMember20841000JPY
Proceeds from long term loans payable fin cfPrior1YTDDuration_NonConsolidatedMember100000000JPY
Proceeds from long term loans payable fin cfCurrentYTDDuration_NonConsolidatedMember100000000JPY
Repayment of long term loans payable fin cfPrior1YTDDuration_NonConsolidatedMember-66672000JPY
Repayment of long term loans payable fin cfCurrentYTDDuration_NonConsolidatedMember-72220000JPY
Net increase decrease in short term loans payable fin cfPrior1YTDDuration_NonConsolidatedMember－JPY
Net increase decrease in short term loans payable fin cfCurrentYTDDuration_NonConsolidatedMember2786000JPY
Repayments of lease obligations fin cfPrior1YTDDuration_NonConsolidatedMember-1294000JPY
Repayments of lease obligations fin cfCurrentYTDDuration_NonConsolidatedMember-907000JPY
Proceeds from issuance of common stock fin cfPrior1YTDDuration_NonConsolidatedMember3085224000JPY
Proceeds from issuance of common stock fin cfCurrentYTDDuration_NonConsolidatedMember－JPY
Proceeds from issuance of subscription rights to shares fin cfPrior1YTDDuration_NonConsolidatedMember42902000JPY
Proceeds from issuance of subscription rights to shares fin cfCurrentYTDDuration_NonConsolidatedMember－JPY
Purchase of treasury stock fin cfPrior1YTDDuration_NonConsolidatedMember－JPY
Purchase of treasury stock fin cfCurrentYTDDuration_NonConsolidatedMember-28000JPY
Other payments fin cfPrior1YTDDuration_NonConsolidatedMember-11390000JPY
Other payments fin cfCurrentYTDDuration_NonConsolidatedMember-30000JPY
Net cash provided by used in financing activitiesPrior1YTDDuration_NonConsolidatedMember3148769000JPY
Net cash provided by used in financing activitiesCurrentYTDDuration_NonConsolidatedMember29599000JPY
Effect of exchange rate change on cash and cash equivalentsPrior1YTDDuration_NonConsolidatedMember25304000JPY
Effect of exchange rate change on cash and cash equivalentsCurrentYTDDuration_NonConsolidatedMember76061000JPY
Net increase decrease in cash and cash equivalentsPrior1YTDDuration_NonConsolidatedMember2579157000JPY
Net increase decrease in cash and cash equivalentsCurrentYTDDuration_NonConsolidatedMember-595979000JPY
Cash and cash equivalentsPrior2YearInstant_NonConsolidatedMember1822850000JPY
Cash and cash equivalentsPrior1YearInstant_NonConsolidatedMember3209635000JPY
Cash and cash equivalentsPrior1QuarterInstant_NonConsolidatedMember4402007000JPY
Cash and cash equivalentsCurrentQuarterInstant_NonConsolidatedMember2613656000JPY
Directors compensations sgaPrior1YTDDuration_NonConsolidatedMember125544000JPY
Directors compensations sgaCurrentYTDDuration_NonConsolidatedMember46626000JPY
Salaries and allowances sgaPrior1YTDDuration_NonConsolidatedMember157312000JPY
Salaries and allowances sgaCurrentYTDDuration_NonConsolidatedMember130474000JPY
Research and development expenses sgaPrior1YTDDuration_NonConsolidatedMember321294000JPY
Research and development expenses sgaCurrentYTDDuration_NonConsolidatedMember585265000JPY
Business consignment expenses sgaPrior1YTDDuration_NonConsolidatedMember42679000JPY
Business consignment expenses sgaCurrentYTDDuration_NonConsolidatedMember44629000JPY
License fee sgaPrior1YTDDuration_NonConsolidatedMember16494000JPY
License fee sgaCurrentYTDDuration_NonConsolidatedMember10978000JPY
Document title cover pageFilingDateInstant
Original text (Japanese)四半期報告書
Clause of stipulation cover pageFilingDateInstant
Original text (Japanese)金融商品取引法第24条の４の７第１項
Place of filing cover pageFilingDateInstant
Original text (Japanese)関東財務局長
Filing date cover pageFilingDateInstant2022-08-05
Quarterly accounting period cover pageFilingDateInstant
Original text (Japanese)第19期 第２四半期(自　2022年４月１日　至　2022年６月30日)
Company name cover pageFilingDateInstant
Original text (Japanese)オンコリスバイオファーマ株式会社
Company name in english cover pageFilingDateInstantOncolys BioPharma Inc.
Title and name of representative cover pageFilingDateInstant
Original text (Japanese)代表取締役社長　浦田 泰生
Address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)東京都港区虎ノ門四丁目１番28号

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identitynon_consolidated 2021-12-31pass
balance sheet identitynon_consolidated 2022-06-30pass
dei present pass
period resolution pass
statement vs summary · net assetsnon_consolidated 2021-12-31pass
statement vs summary · net assetsnon_consolidated 2022-06-30pass
statement vs summary · operating cash flownon_consolidated 2021-01-01/2021-06-30pass
statement vs summary · operating cash flownon_consolidated 2022-01-01/2022-06-30pass
statement vs summary · revenuenon_consolidated 2021-01-01/2021-06-30pass
statement vs summary · revenuenon_consolidated 2022-01-01/2022-06-30pass
statement vs summary · total assetsnon_consolidated 2021-12-31pass
statement vs summary · total assetsnon_consolidated 2022-06-30pass